TITLE

CuraGen reports revenue increased 63% last year

PUB. DATE
March 2000
SOURCE
Biotech Financial Reports;Mar2000, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the financial performance posted by New Haven, Connecticut-based biotechnology firm CuraGen Corp. for the fourth quarter and the year ended December 31, 1999. Pharmaceutical companies with which CuraGen established collaborations; Asset impairment charge; Application of genomics to develop life sciences products.
ACCESSION #
2819975

 

Related Articles

  • OTHER NEWS TO NOTE.  // BioWorld Today;6/20/2007, Vol. 18 Issue 119, p2 

    This section offers news briefs on the biotechnology industry in the U.S. A.P. Pharma Inc. completed a public offering of 24.39 million shares of common stock. Abraxis BioScience Inc. entered an agreement with the University of Southern California that provides Abraxis exclusive worldwide rights...

  • CuraGen receives orphan drug designation for compound targeting oral mucositis.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p12 

    Reports that the U.S. Food and Drug Administration has granted CuraGen Corp.'s CG53135 compound orphan drug designation status. Evaluation of the safety and pharmacokinetics of CG53135 in patients with oral mucositis; Response of patients treated with CG53135; Causes of oral mucositis.

  • OTHER NEWS TO NOTE.  // BioWorld Today;2/19/2009, Vol. 20 Issue 32, p2 

    This section offers news briefs on the biotechnology industry. Acusphere Inc. has amended its new drug application (NDA) for Imagify, a perflubutane polymer microspheres for injectable suspension. The U.S. Food and Drug Administration (FDA) has accepted the biologics license application filed by...

  • Regulatory News Headlines February 15, 2004 - March 14, 2004.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p11 

    Reports on developments related pharmaceutical biotechnology industry in the U.S. from February 15, 2004 to March 14, 2004. Plans of Biogen Idec Inc. and Elan Corp. PLC to file for the U.S. Food and Drug Administration (FDA) approval of Antegren; Designation for CuraGen Corp.'s compound...

  • On the Up and Up. Branca, Malorye A.; Hoffer, David; Van Der Brugge, Bas // Bio-IT World;Feb2004, Vol. 3 Issue 2, p32 

    Reports on the market performance of pharmaceutical and biotechnology companies in the U.S. in the fourth quarter of 2003. Comparison of the market value growth of drug developers and tools companies; Impact of the approval of the anti-cancer drug Velcade on the market capitalization of...

  • CuraGen Corporation SWOT Analysis.  // CuraGen Corporation SWOT Analysis;Feb2008, p1 

    A company profile of CuraGen Corp., a biopharmaceutical company engaged in the development of pharmaceutical products in the areas of oncology, inflammatory disease and diabetes, is presented. An overview of the company is given, along with key facts including contact information, number of...

  • Company Overview.  // CuraGen Corporation SWOT Analysis;Feb2008, p4 

    An overview of CuraGen Corp., a biopharmaceutical company engaged in the development of pharmaceutical products in the areas of oncology, inflammatory disease and diabetes, is presented. Data is included on revenues generated in fiscal year ended December 2006, as well as principal business...

  • Key Facts.  // CuraGen Corporation SWOT Analysis;Feb2008, p4 

    Key facts about CuraGen Corp., a biopharmaceutical company engaged in the development of pharmaceutical products in the areas of oncology, inflammatory disease and diabetes, are presented. Address and contact information is given, as well as statistics on revenues, financial year end data and...

  • SWOT Analysis.  // CuraGen Corporation SWOT Analysis;Feb2008, p5 

    A business analysis of CuraGen Corp., a biopharmaceutical company engaged in the development of pharmaceutical products in the areas of oncology, inflammatory disease and diabetes, is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics